Table 2.

Significantly dysregulated miRNA in the comparison of malignant versus benign thyroid tissuesa within discovery specimens

Model 1Model 2Model 3
miRNALog2FCPPadjC-statisticbPP
hsa-miR-146b*3.38.3E−142.2E−110.8983.5E−111.9E−11
hsa-miR-146b1.96.7E−096.6E−070.8872.7E−071.3E−07
hsa-miR-2221.57.5E−096.6E−070.8972.8E−078.9E−09
hsa-miR-2211.62.0E−081.3E−060.8739.3E−079.4E−08
hsa-miR-134−2.54.1E−072.2E−050.2014.8E−061.4E−04
hsa-miR-34a1.33.1E−061.3E−040.8487.1E−053.3E−06
hsa-miR-101−1.04.0E−061.5E−040.1209.1E−069.1E−06
hsa-miR-143*1.71.7E−055.7E−040.7821.9E−041.2E−04
hsa-miR-144*−1.71.5E−044.2E−030.2103.6E−041.3E−04
hsa-miR-615*−2.51.6E−044.2E−030.2404.9E−041.2E−02
hsa-miR-3751.52.8E−046.7E−030.7503.5E−035.5E−03
hsa-miR-181b0.83.0E−046.7E−030.6967.2E−048.8E−06
hsa-miR-194−1.04.1E−048.4E−030.2221.7E−043.0E−03
hsa-miR-130a−0.95.9E−041.1E−020.2644.4E−035.2E−04
hsa-miR-199a-3p−0.81.1E−031.9E−020.2447.4E−033.7E−03
hsa-miR-30a−0.61.2E−032.0E−020.2174.6E−037.9E−03
hsa-miR-4240.71.5E−032.2E−020.7811.4E−034.9E−03
hsa-miR-148a−0.61.5E−032.2E−020.2215.6E−039.5E−03
hsa-miR-240.71.9E−032.7E−020.8163.0E−031.7E−02
  • Abbreviations: Log2FC, log base 2 of the fold change; Padj, P value adjusted for multiple testing (false detection rate).

  • aModel 1 refers to patient-adjusted analysis; Model 2 includes patient and thyroid function state (euthyroid, hypothyroid, or hyperthyroid); and Model 3 includes patient and presence of noncancer thyroid pathology (Hashimoto thyroiditis or Graves disease).

  • bThe area under the ROC curve, which corresponds to the discrimination ability between malignant and benign samples (values closer to 0 or 1 represent higher discrimination ability, whereas values approaching 0.5 signify lack of discrimination).